Sartorius and Sanofi Collaboration: Advancements in Biomanufacturing

Sanofi is a global pharmaceutical company headquartered in Paris, engaged in research, manufacturing, and distribution of pharmaceutical products. Sartorius offers a wide range of applications for upstream and downstream process intensification, from high-throughput process development tools to scalable, flexible manufacturing solutions. The selection of Sartorius as a preferred partner demonstrates its leading position in process intensification.

Integrated and continuous biomanufacturing (ICB) is an advanced approach to biopharmaceutical production. The concept aims to maximize efficiency by enabling continuous and steady material flow, as opposed to traditional batch production methods, and by integrating multiple units into the process. ICB reduces the overall process footprint, leading to lower raw material and energy consumption, higher productivity, and less waste.

Sartorius will gain authorized access to prototypes and patents developed by Sanofi and contribute to the development of the ICB platform with its engineering and cutting-edge technological solutions, with exclusive rights to commercialize the ICB platform for customers worldwide.

Technological innovation is crucial for biopharmaceutical companies to significantly reduce the cost of drug manufacturing - while improving the environmental footprint of their operations – and ultimately getting life-saving drugs to patients faster. As the biologics landscape becomes more diverse, teaming up with Sanofi is an excellent basis for developing a unique modular platform that combines flexibility with the advantages of intensified bioprocessing. This collaboration will help Sartorius to further expand its position as a leading company in the field of integrated and continuous bioprocessing,

Jan Schäfer, Head of Separation Systems at Sartorius

Official Announcement: Sartorius and Sanofi Business Collaboration